Tissue-agnostic cancer therapies: promise, reality, and the path forward.
Where this comes from
- Record sourced from PubMed, PMID 40436909.
- Also identified by DOI 10.1038/s41467-025-60369-1 and PMC identifier 12120101.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progress depends on universal genomic testing, an oncogenomic-savvy workforce, innovative trials, updated regulations, and real-world evidence to maximize potential.